OBT & Seattle Genetics join forces for antibody conjugates in cancer
This article was originally published in Scrip
Signing its third deal in as many weeks, Oxford BioTherapeutics (OBT) has agreed to collaborate with Seattle Genetics to discover jointly novel antibody-drug conjugates (ADC) as potential cancer treatments. OBT will generate panels of monoclonal antibodies against novel tumour-specific antigens identified using its proprietary Oxford Genome Anatomy Project (OGAP) proteomic database. Seattle Genetics will use its ADC platform to screen the resulting monoclonals for activity.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.